当前位置:考试网  > 试卷库  > 技能鉴定  > 交通相关  > 铁路职业技能鉴定  > 铁路售票员  > 如何发售团体旅客票?
试题预览

如何发售团体旅客票?

查看答案
收藏
纠错
正确答案:

(1)20 人以上乘车日期、车次、到站、 座别相同的旅客集体乘车为团体旅客,承运人要优先安排;

(2) 填发代用票时,除持代用票本人外, 每人另发一张团休旅客证,号码记载在代用票记事栏内;

(3) 满20人时,给予免收一个人的优惠, 20人以上,每增加 10人,再免收一个人的票款但每年春运期间不予优惠。

答案解析:

暂无解析

你可能感兴趣的试题

事实前提的特点主要表现在()、()和()三个方面。

横式结构在段落层次间体现出()。

下列公关启事属于公务启事的是()。

具有法人资格的社会组织之间,在各自的经营管理权限和业务范围内,按照法律规定,在平等互利的原则下,明确各自的权利与义务而共同订立和遵守的书面协议是()

下列公关启事属于公务启事的是()

热门试题 更多>
试题分类: 口语
练习次数:0次
1.The failure of a high-profile cholesterol drug has thrown a spotlight on the complicated machinery that regulates cholesterol levels.But many researchers remain confident that drugs to boost levels of 'good' cholesterol are still one of the most promising means to combat spiralling heart disease. 2.Drug company Pfizer announced on 2 December that it was cancelling all clinical trials of torcetrapib,a drug designed to raise heart-protective high-density lipoproteins (HDLs).In a trial of 15000 patients,a safety board found that more people died or suffered cardiovascular problems after taking the drug plus a cholesterol-lowering statin than those in a control group who took the statin alone. 3.The news came as a kick in the teeth to many cardiologists because earlier tests in animals and people suggested it would lower rates of cardiovascular disease."There have been no red flags to my knowledge," says John Chapman,a specialist in lipoproteins and atherosclerosis at the National Institute for Health and Medical Research (INSERM) in Paris who has also studied torcetrapib."This cancellation came as a complete shock." 4.Torcetrapib is one of the most advanced of a new breed of drugs designed to raise levels of HDLs,which ferry cholesterol out of artery-clogging plaques to the liver for removal from the body.Specifically,torcetrapib blocks a protein called cholesterol ester transfer protein (CETP),which normally transfers the cholesterol from high-density lipoproteins to low density,plaque-promoting ones.Statins,in contrast,mainly work by lowering the 'bad' low-density lipoproteins. Under pressure 5.Researchers are now trying to work out why and how the drug backfired,something that will not become clear until the clinical details are released by Pfizer.One hint lies in evidence from earlier trials that it slightly raises blood pressure in some patients.It was thought that this mild problem would be offset by the heart benefits of the drug.But it is possible that it actually proved fatal in some patients who already suffered high blood pressure.If blood pressure is the explanation,it would actually be good news for drug developers because it suggests that the problems are specific to this compound.Other prototype drugs that are being developed to block CETP work in a slightly different way and might not suffer the same downfall. 6.But it is also possible that the whole idea of blocking CETP is flawed,says Moti Kashyap,who directs atherosclerosis research at the VA Medical Center in Long Beach,California.When HDLs excrete cholesterol in the liver,they actually rely on LDLs for part of this process.So inhibiting CETP,which prevents the transfer of cholesterol from HDL to LDL,might actually cause an abnormal and irreversible accumulation of cholesterol in the body."You're blocking a physiologic mechanism to eliminate cholesterol and effectively constipating the pathway," says Kashyap.Going up 7.Most researchers remain confident that elevating high density lipoproteins levels by one means or another is one of the best routes for helping heart disease patients.But HDLs are complex and not entirely understood.One approved drug,called niacin,is known to both raise HDL and reduce cardiovascular risk but also causes an unpleasant sensation of heat and tingling.Researchers are exploring whether they can bypass this side effect and whether niacin can lower disease risk more than statins alone.Scientists are also working on several other means to bump up high-density lipoproteins by,for example,introducing synthetic HDLs."The only thing we know is dead in the water is torcetrapib,not the whole idea of raising HDL," says Michael Miller,director of preventive cardiology at the University of Maryland Medical Center,Baltimore. Questions 7-13 Match torcetrapib,HDLs,statin and CETP with their functions (Questions 8-13)..Write the correct letter A,B,C or D in boxes 8-13 on your answer sheet.NB You may use any letter more than once. 7.It has been administered to over 10,000 subjects in a clinical trial. 8.It could help rid human body of cholesterol. 9.Researchers are yet to find more about it. 10.It was used to reduce the level of cholesterol. 11.According to Kashyap,it might lead to unwanted result if it's blocked. 12.It produced contradictory results in different trials. 13.It could inhibit LDLs.List of choices A.TorcetrapicB.HDLSC.StatinD.CETP
试题分类: 阅读
练习次数:3次
扫一扫,手机做题